NanOlogy, LLC, a Texas-based clinical-stage oncology company, has announced the launch of a drug development program focused on diffuse intrinsic pontine glioma, known as DIPG, a universally fatal pediatric brainstem tumor. The company is advancing Large Surface Area Microparticle Cisplatin, or LSAM-cisplatin, designed for stereotactic intratumoral administration in children. Investigational New Drug–enabling studies are underway, […]
Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.
Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.
TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.
ProVerum wins FDA approval for ProVee, a permanent urethral stent for BPH offering fast recovery and no catheter. See how it could disrupt the urology device market.
Eli Lilly and Indiana University are launching a $40M clinical trial and Alzheimer’s research initiative in Indiana. See what it could mean for U.S. pharma.
